Posted by Michael Wonder on 10 Sep 2021
MHRA approves Amgen’s Lumykras under Project Orbis
10 September 2021 - Amgen has announced that is first-in-class KRAS G12C inhibitor Lumykras (sotorasib) has been received a conditional marketing authorisation in the UK.
The UK MHRA has conditionally approved Lumykras under Project Orbis – an international collaborative programme between the US FDA and regulatory agencies across the world.
